Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B

Liver International

Volumn 32, Issue 1, 2012, Pages 137-146

  Minde, Zeng ^a   Yimin, Mao ^a,b   Guangbi, Yao ^b   Jinlin, Hou ^c   Hao, Wang ^d   Hong, Ren ^e   Yuming, Wang ^e   Xiaqiu, Zhou ^a   Daozhen, Xu ^f   Yagang, Chen ^g   Junqi, Niu ^h   Youming, Chen ⁱ   Yaozong, Wang ^j   Dixon, Jonathan ^k   Barker, Keith ^k  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Jing An Qu Central Hospital   (China)

^c FIRST MILITARY MEDICAL UNIVERSITY   (China)

^d Beijing People's Hospital   (China)

^e CHONGQING MEDICAL UNIVERSITY   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g ZHEJIANG UNIVERSITY   (China)

^h JILIN UNIVERSITY   (China)

ⁱ SUN YAT SEN UNIVERSITY   (China)

^j JiNan Hospital for Infectious Disease   (China)

^k GlaxoSmithKine International   (United Kingdom)

more..

Author keywords

Alanine aminotransferase; Antiviral agents; Drug resistance; Extended treatment; Viral; Viral load

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; HEPATITIS E ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; CHINESE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS RESISTANCE;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 83255162071     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02641.x     Document Type: Article

References (21)

1. World Health Organization. Hepatitis B. Geneva: World Health Organization, 2000. Factsheet No.: 204, October 2000.
2. Lai C, Ratzui V, Yuen M-F, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.
3. Lok A, Mcmahon B. Chronic hepatitis B: update 2009 (AASLD Practice Guidelines). Hepatol 2009; 50: 1-36.
4. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
5. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
6. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
7. Marcellin P, Chang T, Lim S, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
8. Marcellin P, Chang T-T, Lim S-G, et al. Adefovir dipivoxil (ADV) 10 mg for the treatment of patients with HBeAg+ chronic hepatitis B: continued efficacy beyond 48 weeks (abstract no. 840). Hepatol 2002; 36(4 Pt. 2): 373A.
9. Marcellin P, Sievert W, Tong M, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time (abstract no. 1135). Hepatol 2004; 40(4 Suppl 1): 655A.
10. Marcellin P, Chang T-T, Lim S, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients (abstract no. 969). Hepatol 2006; 44(4 Suppl 1): 548A.
11. Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatol 2006; 44: 108-16.
12. Leung N, Lai C-L, Chang T-T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatol 2001; 33: 1527-32.
13. Chang T-T, Lai C-L, Chien R-N, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
14. Chang T-T, Gish R, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
15. Chang T-T, Lai C-L, Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatol 2010; 51: 422-30.
16. Wang Y, Thongsawat S, Gane E, et al. Efficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB) (abstract no. 482). Hepatol 2009; 50(4 Suppl): 533A.
17. Heathcote E, Gane E, De Man RA, et al. Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103), preliminary analysis (abstract no. 483). Hepatol 2009; 50(4 Suppl): 533A-4A.
18. Yuen M-F, Seto W-K, Chow D-F, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antiviral Ther 2007; 12: 1295-303.
19. Liaw Y-F, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
20. Tenney D, Rose R, Baldick C, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatol 2009; 49: 1503-14.
21. Tenney D, Pokornowski K, Rose R, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients (abstract no. 20). J Hepatol 2009; 50(Suppl 1): S10.